As of the latest SEC filings, insiders at Aduro BioTech, Inc. (NASDAQ:ADRO) have seen transactions decrease by -37.42% over the past 6 months. Insiders now own 0.80% of total outstanding shares.
Insiders buy and sell their own company’s stock every day, though the trading is restricted. The SEC says that an “insider” is anyone who owns at least a 10% stake in a company’s stock. Insiders who make trades are required to file all of their transactions within two business days of the initial transaction date. Information about legal insider trading is extremely valuable to investors. After all, if insiders are buying stock in their own company, they probably know something that a normal investor does not. Due to the fact that insiders are prevented from trading stock within a six-month period, it can be assumed that they are buying their own shares because they are confident that their company will be a top performer over a long period of time. One of the greatest investors of all time, Peter Lynch, is quoted as saying: “insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.”
University of Michigan professor and noted insider trading researcher, Nejat Seyhun, discovered that when insiders bought shares of their own companies, the stocks outperformed the total market by 8.9% over the following year while when they sold shares, the stock underperformed 5.4% over the same period.
Aduro BioTech, Inc. (NASDAQ:ADRO) stands 1.96% away from its 50-day simple moving average and also -3.64% away from the 200-day average. Recently, the equity stands -46.67% away from the 52-week high and 69.42% from the 52-week low. The RSI (Relative Strength Index), an indicator that shows price strength by comparing upward and downward close-to-close movements is 53.66.
The consensus analysts recommendation at this point stands at 1.80 for Aduro BioTech, Inc. (NASDAQ:ADRO). This is based on a 1-5 scale where 1 indicates a Strong Buy and 5 a Strong Sell. Further, analysts have a 12 month target price of $18.33 on company shares. This is according to the analysts polled by Thomson Reuters which have recently published research reports on the firm.